Introduction
The Anti-Human SLC22A2/OCT2 Monoclonal Antibody (1A709) is a highly specific and potent antibody that targets the human SLC22A2/OCT2 protein. This protein, also known as the organic cation transporter 2 (OCT2), is a member of the solute carrier family and is involved in the transport of various organic cations across cell membranes. The 1A709 antibody is a valuable tool for research and has been extensively studied for its structure, activity, and potential applications.
Structure of Anti-Human SLC22A2/OCT2 Monoclonal Antibody (1A709)
The 1A709 antibody is a monoclonal antibody, meaning it is produced by a single type of immune cell and is highly specific to its target protein. It is composed of two heavy chains and two light chains, each with a unique amino acid sequence that determines its binding specificity. The 1A709 antibody specifically binds to the extracellular domain of the SLC22A2/OCT2 protein, preventing its interaction with other molecules and inhibiting its activity.
Activity of Anti-Human SLC22A2/OCT2 Monoclonal Antibody (1A709)
The SLC22A2/OCT2 protein is primarily expressed in the kidney, liver, and brain, and is responsible for the transport of a wide range of cationic compounds, including drugs, toxins, and endogenous metabolites. The 1A709 antibody has been shown to effectively block the transport activity of SLC22A2/OCT2, thereby inhibiting the uptake of these compounds into cells. This makes it a valuable tool for studying the role of SLC22A2/OCT2 in drug uptake and metabolism, as well as its potential involvement in various diseases.
Applications of Anti-Human SLC22A2/OCT2 Monoclonal Antibody (1A709)
The 1A709 antibody has been extensively used in research to study the function and regulation of SLC22A2/OCT2. It has also been used in various in vitro and in vivo studies to investigate the role of SLC22A2/OCT2 in the transport and pharmacokinetics of drugs. Additionally, the 1A709 antibody has shown potential for therapeutic applications, particularly in the treatment of diseases where SLC22A2/OCT2 plays a critical role.
Role in drug transport and pharmacokinetics
The SLC22A2/OCT2 protein is known to play a crucial role in the uptake and elimination of many drugs, including anticancer agents, antivirals, and antibiotics. The 1A709 antibody has been used to study the impact of SLC22A2/OCT2 on drug transport and pharmacokinetics, providing valuable insights into drug efficacy and toxicity. It has also been used to develop novel drug delivery strategies that target SLC22A2/OCT2, potentially improving drug efficacy and reducing adverse effects.
Potential therapeutic applications
The SLC22A2/OCT2 protein has been implicated in various diseases, including cancer, diabetes, and neurological disorders. The 1A709 antibody has shown promise as a therapeutic agent in these diseases by targeting SLC22A2/OCT2 and modulating its activity. For example, in cancer, the 1A709 antibody has been used to inhibit the uptake of chemotherapeutic drugs into cancer cells, potentially improving treatment outcomes. In diabetes, the antibody has been shown to reduce glucose uptake in the liver, providing a potential treatment for hyperglycemia.
Conclusion
In summary, the Anti-Human SLC22A2/OCT2 Monoclonal Antibody (1A709) is a highly specific and potent antibody that targets the SLC22A2/OCT2 protein. Its structure and activity have been extensively studied, and it has shown great potential in various research
There are no reviews yet.